Douglas A. Nelson, MD

Articles

Dr. Nelson on the Future Utility of ctDNA in CRC

June 5th 2020

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

Dr. Nelson on Why Patients With mCRC are Often Referred to Surgeons First

May 22nd 2020

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Dr. Nelson on Why Patients With mCRC are Often Referred to Surgeons First

May 21st 2020

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Dr. Nelson on the CheckMate-142 Trial in MSI-H/dMMR mCRC

March 27th 2020

Douglas A. Nelson, MD, discusses results from the CheckMate-142 in metastatic colorectal cancer.

Dr. Nelson on QOL Data From the BEACON CRC Trial in mCRC

March 26th 2020

Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.

Dr. Nelson on the Benefit of Primary Tumor Resection in mCRC

March 11th 2020

Douglas A. Nelson, MD, associate professor in the Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of primary tumor resection in patients with metastatic colorectal cancer (mCRC).

Dr. Nelson on Novel Combination Therapies in Colorectal Cancer

February 19th 2019

Douglas A. Nelson, MD, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel combination therapies in colorectal cancer (CRC).